Interpace Biosciences, Inc. (IDXG)
6.025
-0.36
(-5.71%)
USD |
OTCM |
Oct 02, 16:00
Interpace Biosciences Gross Profit Margin (Quarterly) : 61.91% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.91% |
| March 31, 2026 | 65.37% |
| December 31, 2025 | 65.52% |
| September 30, 2025 | 62.12% |
| June 30, 2025 | 57.15% |
| March 31, 2025 | 64.00% |
| December 31, 2024 | 63.70% |
| September 30, 2024 | 64.27% |
| June 30, 2024 | 64.82% |
| March 31, 2024 | 62.01% |
| December 31, 2023 | 62.04% |
| September 30, 2023 | 52.38% |
| June 30, 2023 | 59.11% |
| March 31, 2023 | 57.60% |
| December 31, 2022 | 56.34% |
| September 30, 2022 | 53.90% |
| June 30, 2022 | 31.72% |
| March 31, 2022 | 42.95% |
| December 31, 2021 | 49.30% |
| September 30, 2021 | 43.97% |
| June 30, 2021 | 38.04% |
| March 31, 2021 | 34.63% |
| December 31, 2020 | 20.88% |
| September 30, 2020 | 23.51% |
| June 30, 2020 | 8.83% |
| Date | Value |
|---|---|
| March 31, 2020 | 20.21% |
| December 31, 2019 | -60.55% |
| September 30, 2019 | 23.44% |
| June 30, 2019 | 37.35% |
| March 31, 2019 | 42.85% |
| December 31, 2018 | 41.38% |
| September 30, 2018 | 37.84% |
| June 30, 2018 | 44.37% |
| March 31, 2018 | 29.44% |
| December 31, 2017 | 43.89% |
| September 30, 2017 | 31.41% |
| June 30, 2017 | 30.17% |
| March 31, 2017 | 25.53% |
| December 31, 2016 | 15.57% |
| September 30, 2016 | 15.08% |
| June 30, 2016 | 22.15% |
| March 31, 2016 | 29.19% |
| September 30, 2015 | 17.05% |
| June 30, 2015 | 14.06% |
| March 31, 2015 | 17.68% |
| December 31, 2014 | 12.91% |
| September 30, 2014 | 0.19% |
| June 30, 2014 | 2.94% |
| March 31, 2014 | 4.78% |
| December 31, 2013 | 0.79% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| PD-Rx Pharmaceuticals, Inc. | -- |
| Medical Marijuana, Inc. | 83.04% |
| Acro Biomedical Co. Ltd. | -- |
| Stella Diagnostics, Inc. | -14.09% |
| ZeroStack Corp. | -7.63% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 185.0% |
| Return on Assets | 98.52% |
| Return on Invested Capital | 163.9% |
| Profit Margin (Quarterly) | 2.91% |
| Operating Margin (Quarterly) | 3.52% |
| Return on Net Operating Assets | 235.8% |